AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants, opening up a major new market for the would-be blockbuster.Beyfortus (nirsevimab) has also been approved in the US and Canada, EU, and GB, and is under review in other countries, including […]
